1316216-05-3

Basic information

• Product Name: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate
• Synonyms: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate
• CAS NO: 1316216-05-3
• Molecular Formula: C₁₉H₁₇N₃O₂
• Molecular Weight: 319.35718
• Mol File: 1316216-05-3.mol
• Article Data: 27

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate(1316216-05-3)
• EPA Substance Registry System: Ethyl-2-(diphenylaMino)pyriMidine-5-carboxylate(1316216-05-3)

Safety Data

• Hazardous Substances Data: 1316216-05-3(Hazardous Substances Data)

Upstream product

• 95928-49-7 2-hydroxy-pyrimidine-5-carboxylic acid ethyl ester 
• 591-50-4 iodobenzene 
• 864172-93-0 ethyl 2-(phenylamino)pyrimidine-5-carboxylate 
• 62-53-3 aniline 
• 89793-12-4 ethyl 2-chloropyrimidine-5-carboxylate 

Downstream Products

• 1316216-07-5 C₂₅H₂₈N₄O₃ 
• 1316214-52-4 N-[7-(hydroxyamino)-7-oxo-heptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide 
• 1316216-06-4 C₁₇H₁₃N₃O₂ 

Relevant articles and documents

Mercapto compounds as histone deacetylase inhibitors and uses thereof

Experimental results show, that the compound shown by the invention has high blood-brain barrier permeability, on normal cytotoxic low, potential cardiac toxicity, and higher blood-brain barrier permeability of, on a cell model as a compound shown, or a pharmaceutically acceptable salt, ester or a prodrug, of the compound as a high-efficiency low-toxicity anti-tumor or neurodegenerative disease therapeutic agent shown in the invention. The compound has high blood-brain barrier permeability . The compound of the present invention has higher blood-brain barrier permeability as shown in the development prospect (I) of, a: therapeutic agent for high-efficiency and low-toxicity antitumor or neurodegenerative diseases.

PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USE THEREOF

The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND EPOTHILONE AND METHODS OF USE THEREOF

The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an epothilone, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.